We have demonstrated that pharmacological blockade of AT-II and AT1R signaling by these agents significantly suppressed tumor growth and angiogenesis with reduced intratumor VEGF production in a mouse HCC allograft model [19]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.